Jonathan Violin - 23 Jan 2026 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Reporting relationship: Director
Issuer ticker: ATXS
Reported as of: 23 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 16:37:09 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Harshbarger, as attorney-in-fact for Jonathan Violin

Key filing fact

Jonathan Violin filed Form 4 for Astria Therapeutics, Inc. (ATXS) on 23 Jan 2026.

Key facts

This page summarizes Jonathan Violin's Form 4 filing for Astria Therapeutics, Inc. (ATXS).
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 23 Jan 2026, 16:37.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730615 Primary reporting owner

Violin Jonathan

Relationship: Director
Address: C/O ASTRIA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON
Signature: /s/ Ben Harshbarger, as attorney-in-fact for Jonathan Violin
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATXS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -263,321
Change %: -100%
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +14,166
Change %
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,166
Exercise price: $12.24
Footnotes: F2, F3

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +8,333
Change %
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,333
Exercise price: $3.00
Footnotes: F3

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +14,100
Change %
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,100
Exercise price: $11.35
Footnotes: F3

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +14,100
Change %
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,100
Exercise price: $9.18
Footnotes: F3

ATXS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: +26,550
Change %
Price
Shares after: 0
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,550
Exercise price: $5.79
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jonathan Violin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes.

Footnote F2

These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

Footnote F3

At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC remarks

At the Effective Time, each Issuer stock option for which the applicable exercise price was equal to or greater than $13.00 (each, an "Out-of-the-Money Option") that was outstanding immediately prior to the Effective Time was canceled for no consideration, which cancelation is exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-4(d) and Rule 16b-6(d) thereunder. Accordingly, the Reporting Person's Out-of-the-Money Options that were canceled in the Merger are not reported herein.